RLY-2608,Fulvestrant
relay therapeutics
['mbc', 'bcsm', ' fulv', 'breast', 'solid tumor', 'rly-2608']
first-in-human study of mutant-selective pi3k inhibitor, rly-2608, as a single agent in advanced solid tumor patients and in combination with fulvestrant in patients with advanced breast cancer. #asco23 #mbc #bio23 #bcsm #metastaticbreastcancer 